Scientific Breakthroughs and Industry Players in Anti-Aging Discovery

Review Article

Abstract

The pursuit of human longevity is a rigorously funded sector of biotechnology known as geroscience. This field operates on the premise that aging is a malleable biological process driven by distinct molecular hallmarks, rather than an inevitable decline. Current research focuses on intervening in these upstream mechanisms such as cellular senescence, mitochondrial dysfunction, and epigenetic alterations to extend healthspan, the period of life spent in good health. Significant capital influx from the technology sector has catalyzed this shift, leading to a unique convergence of computational biology, artificial intelligence, and regenerative medicine. The industry landscape is now populated by a mix of high-profile ventures backed by billionaires and agile biotech startups utilizing venture-building models to de-risk portfolio development. However, the market faces substantial friction from regulatory guidelines that do not currently recognize aging as a clinically treatable indication, forcing companies to target specific age-related pathologies as proxies for broader longevity claims. Despite these hurdles, the global anti-aging market is projected to expand robustly, driven by an aging global demographic and breakthroughs in proteomic and genomic interventions. This article reviews the scientific pillars supporting these therapies, the competitive strategies of the main industry stakeholders, and the economic forces shaping the commercialization of longevity science